These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 20845054)

  • 1. Combination therapy with sorafenib and S-1 for renal cell carcinoma producing granulocyte colony-stimulating factor.
    Kyono Y; Takayama T; Kinoshita M; Kurita Y; Mugiya S; Baba S; Ozono S
    Int J Clin Oncol; 2011 Jun; 16(3):275-8. PubMed ID: 20845054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of the ERK inhibitor AZD6244 and low-dose sorafenib in a xenograft model of human renal cell carcinoma.
    Yuen JS; Sim MY; Sim HG; Chong TW; Lau WK; Cheng CW; Ong RW; Huynh H
    Int J Oncol; 2012 Aug; 41(2):712-20. PubMed ID: 22641227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma.
    Escudier B; Lassau N; Angevin E; Soria JC; Chami L; Lamuraglia M; Zafarana E; Landreau V; Schwartz B; Brendel E; Armand JP; Robert C
    Clin Cancer Res; 2007 Mar; 13(6):1801-9. PubMed ID: 17363536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I/II trial of sorafenib and infliximab in advanced renal cell carcinoma.
    Larkin JM; Ferguson TR; Pickering LM; Edmonds K; James MG; Thomas K; Banerji U; Berns B; de Boer C; Gore ME
    Br J Cancer; 2010 Oct; 103(8):1149-53. PubMed ID: 20842130
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complete response after sequential sunitinib-sorafenib treatment in a patient with renal cell carcinoma: a case report.
    Verzoni E; Lanocita R; Procopio G
    Clin Genitourin Cancer; 2012 Jun; 10(2):130-3. PubMed ID: 22226825
    [No Abstract]   [Full Text] [Related]  

  • 6. Where does the combination of sorafenib and interferon in renal cell carcinoma stand?
    Flaherty KT
    Cancer; 2010 Jan; 116(1):4-7. PubMed ID: 19890962
    [No Abstract]   [Full Text] [Related]  

  • 7. [Tegafur-uracil markedly reduced pulmonary metastasis from renal cell carcinoma refractory to sorafenib, interferon and interleukin 2].
    Morimoto H; Tsuzaka Y; Kaneko T; Matsushima H; Homma Y
    Gan To Kagaku Ryoho; 2010 Oct; 37(10):2007-10. PubMed ID: 20948275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.
    Choueiri TK; Garcia JA; Elson P; Khasawneh M; Usman S; Golshayan AR; Baz RC; Wood L; Rini BI; Bukowski RM
    Cancer; 2007 Aug; 110(3):543-50. PubMed ID: 17577222
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sorafenib: recent update on activity as a single agent and in combination with interferon-alpha2 in patients with advanced-stage renal cell carcinoma.
    Reddy GK; Bukowski RM
    Clin Genitourin Cancer; 2006 Mar; 4(4):246-8. PubMed ID: 16729906
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sorafenib [corrected] in kidney cancer.
    Escudier B
    Ann Oncol; 2007 Jul; 18 Suppl 9():ix90-3. PubMed ID: 17631603
    [No Abstract]   [Full Text] [Related]  

  • 11. Phase I/II study of S-1 in combination with sorafenib for metastatic renal cell carcinoma.
    Naito S; Sakai H; Hashine K; Tomita Y; Shinohara N; Fujisawa M; Eto M; Ozono S; Akaza H
    Ann Oncol; 2015 Sep; 26(9):1871-1876. PubMed ID: 26117830
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum interferon alpha receptor 2 mRNA may predict efficacy of interferon alpha with/without low-dose sorafenib for metastatic clear cell renal cell carcinoma.
    Furuya N; Kamai T; Shirataki H; Yanai Y; Fukuda T; Mizuno T; Nakamura F; Kambara T; Nakanishi K; Abe H; Yoshida K
    Cancer Immunol Immunother; 2011 Jun; 60(6):793-808. PubMed ID: 21350947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Case report of chemotherapeutic control of a gastric cancer producing granulocyte-colony stimulating factor].
    Miyamoto M; Misawa S
    Nihon Shokakibyo Gakkai Zasshi; 2014 Apr; 111(4):748-55. PubMed ID: 24769464
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Autopsy of anaplastic carcinoma of the pancreas producing granulocyte colony-stimulating factor].
    Hayashi H; Eguchi N; Sumimoto K; Matsumoto K; Azakami T; Sumida T; Tamura T; Sumii M; Uraoka N; Shimamoto F
    Nihon Shokakibyo Gakkai Zasshi; 2016 Aug; 113(8):1408-15. PubMed ID: 27498938
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of angiogenic and non-angiogenic targets by sorafenib in renal cell carcinoma (RCC) in a RCC xenograft model.
    Yuen JS; Sim MY; Siml HG; Chong TW; Lau WK; Cheng CW; Huynh H
    Br J Cancer; 2011 Mar; 104(6):941-7. PubMed ID: 21407223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A cross-over response to sequential use of sunitinib after sorafenib in a patient with metastatic renal cell carcinoma.
    Richards TM; Plowman PN; Reznek R; Ball SA
    Clin Oncol (R Coll Radiol); 2009 Oct; 21(8):633-4. PubMed ID: 19380217
    [No Abstract]   [Full Text] [Related]  

  • 17. Safety and efficacy of the combination of erlotinib and sirolimus for the treatment of metastatic renal cell carcinoma after failure of sunitinib or sorafenib.
    Flaig TW; Costa LJ; Gustafson DL; Breaker K; Schultz MK; Crighton F; Kim FJ; Drabkin H
    Br J Cancer; 2010 Sep; 103(6):796-801. PubMed ID: 20823888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metronomic chemotherapy for renal cancer in the landscape of targeted therapy.
    Ravaud A; Grossgoupil M
    Lancet Oncol; 2010 Apr; 11(4):307-8. PubMed ID: 20359658
    [No Abstract]   [Full Text] [Related]  

  • 19. Renal cell cancer presented with leptomeningeal carcinomatosis effectively treated with sorafenib.
    Ranze O; Hofmann E; Distelrath A; Hoeffkes HG
    Onkologie; 2007 Sep; 30(8-9):450-1. PubMed ID: 17848817
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of tumor specimens for a targeted therapy in metastatic renal cell carcinoma patients.
    Raspollini MR
    Curr Oncol Rep; 2007 Sep; 9(5):331. PubMed ID: 17706159
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.